TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

LATEST NEWS

Purdue Pharma Reportedly Offers $10 Billion to $12 Billion for Opioid Settlements
Play
INVESTING

Purdue Pharma to Plead Guilty, Pay $8.3B to Settle Opioid Probe

Purdue Pharma Reportedly Offers $10 Billion to $12 Billion for Opioid Settlements
INVESTING

Purdue Pharma to Plead Guilty, Pay $8.3B to Settle Opioid Probe

Mallinckrodt Inquires Into Sale of Generic Drug Unit
INVESTING

Mallinckrodt Files for Bankruptcy Amid Opioid Litigation

Wall Street NYSE Lead
MARKETS

Apple, Stimulus, Mallinckrodt, Los Angeles Lakers - 5 Things You Must Know Monday

PRESS RELEASES

Mallinckrodt Secures Broad Consensus With Key Stakeholders On Comprehensive Chapter 11 Restructuring

Deals, Bargain Price Make Mallinckrodt a Good Pharma Buy
INVESTING

Mallinckrodt Is Said to Be Near Bankruptcy Deal

PRESS RELEASES

Mallinckrodt's Hobart, N.Y. Site Recognized With Two Manufacturing Leadership Awards

PRESS RELEASES

Mallinckrodt Announces U.S. FDA Filing Acceptance Of Biologics License Application For StrataGraft® Regenerative Skin Tissue For Treatment Of Adults With Deep Partial-thickness Thermal Burns

PRESS RELEASES

Mallinckrodt Announces U.S. Food And Drug Administration (FDA) Advisory Committee Voted To Recommend Terlipressin For Approval To Treat Patients With Hepatorenal Syndrome Type 1 (HRS-1)

PRESS RELEASES

Mallinckrodt To Report Earnings Results For Second Quarter 2020

PRESS RELEASES

Mallinckrodt To Present At The BMO Prescriptions For Success Healthcare Conference

PRESS RELEASES

Mallinckrodt To Proceed With Appeal Despite Appellate Court Decision Denying Temporary Injunction In Ongoing Acthar Gel Medicaid Drug Rebate Dispute With The Centers For Medicare And Medicaid Services (CMS)

PRESS RELEASES

Real-World Data Of Terlipressin In Hospitalized Patients In U.K. With Hepatorenal Syndrome Type 1 (HRS-1) Published In Alimentary Pharmacology And Therapeutics

PRESS RELEASES

Mallinckrodt Completes Rolling Submission Of Biologics License Application For StrataGraft® Regenerative Skin Tissue To U.S. Food And Drug Administration

PRESS RELEASES

Mallinckrodt Will Appeal District Court Ruling In Case Involving Ongoing Acthar Medicaid Drug Rebate Dispute With The Centers For Medicare And Medicaid Services (CMS)

PRESS RELEASES

Mallinckrodt Announces Positive Findings In INOmax® (Nitric Oxide) Gas, For Inhalation Phase 4 Observational Registry In Neonates With Pulmonary Hypertension; Ends Trial Early

PRESS RELEASES

Mallinckrodt Supports Investigator-Initiated Study At Massachusetts General Hospital To Assess Effectiveness Of Inhaled Nitric Oxide In Patients With Severe Acute Respiratory Distress Syndrome Due To COVID-19

PRESS RELEASES

Mallinckrodt Announces U.S. Food And Drug Administration (FDA) Filing Acceptance Of New Drug Application For Terlipressin For Treatment Of Hepatorenal Syndrome Type 1 (HRS-1)

PRESS RELEASES

Mallinckrodt To Report Earnings Results For First Quarter 2020

PRESS RELEASES

Mallinckrodt Announces Publication Of Data On Acthar® Gel (Repository Corticotropin Injection) From Its Randomized, Double-Blind, Placebo-Controlled Phase 4 Study In Rheumatoid Arthritis (RA) In Rheumatology And Therapy

PRESS RELEASES

Mallinckrodt Completes Rolling Submission Of New Drug Application To The U.S. Food And Drug Administration (FDA) For Terlipressin For The Treatment Of Patients With Hepatorenal Syndrome Type 1 (HRS-1)

PRESS RELEASES

Mallinckrodt Evaluates The Potential Role For Inhaled Nitric Oxide To Treat COVID-19 Associated Lung Complications, Engages With Scientific, Governmental And Regulatory Agencies

PRESS RELEASES

Mallinckrodt Initiates Rolling Submission Of New Drug Application To The U.S. Food And Drug Administration (FDA) For Terlipressin For The Treatment Of Patients With Hepatorenal Syndrome Type 1 (HRS-1)

PRESS RELEASES

Mallinckrodt Announces Agreement In Principle For Global Opioid Settlement And Associated Debt Refinancing Activities

PRESS RELEASES

Mallinckrodt To Report Earnings Results For Fourth Quarter And Fiscal 2019